척추 바이오로직스 시장 보고서 : 제품, 수술 유형, 최종사용자, 지역별(2025-2033년)
Spine Biologics Market Report by Product, Surgery Type, End User, and Region 2025-2033
상품코드:1820001
리서치사:IMARC
발행일:2025년 09월
페이지 정보:영문 136 Pages
라이선스 & 가격 (부가세 별도)
ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
한글목차
세계 척추 바이오로직스 시장 규모는 2024년 21억 4,000만 달러에 달했습니다. 향후 IMARC Group은 2033년에는 29억 7,000만 달러에 달할 것으로 예상되며, 2025-2033년간 3.52%의 연평균 성장률(CAGR)을 기록할 것으로 예측하고 있습니다. 이 시장을 이끄는 요인으로는 최소침습수술(MIS)의 보급, 노인 인구의 증가, 소득 수준 향상에 따른 의료 서비스 접근성 확대, 척추 질환 발생률 증가 등이 있습니다.
척추 바이오로직스 시장 분석:
주요 시장 촉진요인 : 척추 바이오로직스 시장 조사에 따르면, 시장은 주로 고령화 및 생활습관 요인과 관련된 추간판 질환 및 척추관 협착증과 같은 척추 질환의 유병률 증가에 의해 주도되고 있습니다.
주요 시장 동향 : 의료 기술의 발전과 함께 조기 회복과 더 나은 치료 결과를 촉진하기 위해 척추 수술에 바이오로직스를 사용하는 경향이 두드러집니다. 척추 바이오로직스 시장 예측에 따르면, 척추 바이오로직스의 정확성과 유효성을 향상시키는 인공지능과 기계학습 기술의 통합으로 업계는 지속적인 혁신을 경험할 것으로 예상됩니다.
지리적 동향 : 북미는 높은 의료 인프라, 높은 의료비, 척추 질환에 대한 인식으로 인해 현재 세계 시장을 선도하고 있습니다. 또한, 척추 바이오로직스 시장 통계에 따르면, 아시아태평양은 의료 접근성 증가, 경제 수준 향상, 노인 인구 증가로 인해 빠르게 성장하고 있습니다.
경쟁 환경 : 척추 바이오로직스 산업의 주요 시장 기업으로는 Arthrex Inc. Inc., Stryker Corporation, Wright Medical Group N.V., Zimmer Biomet 등이 있습니다.
도전과 기회 : 시장 과제에는 바이오로직스의 높은 비용에 대한 우려와 제품 출시를 지연시킬 수 있는 까다로운 규제 환경 등이 있습니다. 척추 바이오로직스 시장 개요에서 설명한 바와 같이, 보험사 및 의료 기관과의 협력 관계의 증가는 바이오로직스 치료에 대한 접근성과 수용성을 향상시킬 수 있는 잠재력을 가지고 있으며, 많은 기회를 창출하고 있습니다.
척추 바이오로직스 시장 동향:
척추 질환의 유병률 증가
척추 질환의 증가는 척추 바이오로직스 시장의 성장에 영향을 미치고 있습니다. 또한, 평균수명의 증가와 생활습관 문제로 인해 추간판 질환, 척추관 협착증 등 퇴행성 질환의 확대에 박차를 가하고 있습니다. 세계보건기구(WHO)에 따르면 2020년에는 약 13명 중 1명, 6억 1,900만 명이 요통(LBP)을 경험하게 될 것이며, 1990년 대비 60% 증가할 것이라고 합니다. 또한, 2050년까지 요통 환자가 약 8억 4,300만 명 증가할 것으로 추정되며, 척추 문제가 광범위하게 확산되고 있음을 강조하고 있습니다. 80대 환자 수가 증가하고 있으며, LBP 환자 수가 증가하고 있는 연령대는 50-55대입니다. 이러한 광범위한 유병률로 인해 뼈의 성장과 치유를 촉진하는 생물의약품을 포함한 효과적인 치료법의 지속적인 개발과 개발이 필요하며, 이러한 광범위한 증상의 치료에 생물의약품이 필수적입니다.
최소침습수술(MIS) 도입 확대
척추질환에 대한 최소침습수술(MIS)은 기존 개복수술에 비해 통증이 적고 회복이 빨라 선호되고 있습니다. IMARC GROUP에 따르면, 최소침습 수술 세계 시장은 2024-2032년 약 6%의 CAGR로 확대될 것으로 예상됩니다. 2023년에는 미국에서 529억 달러, 2032년에는 910억 달러에 달할 것으로 예상됩니다. 이러한 성장은 입원 기간과 회복 기간을 단축하는 수술법으로의 전환을 의미하며, 특히 척추 바이오로직스 시장의 가치에 도움이 될 것입니다.
노인 인구 증가
노인 인구의 증가는 척추 바이오로직스 시장의 수요를 견인하고 있습니다. 나이가 들수록 척추 질환의 발병 위험이 높아져 더 빈번하고 집중적인 치료가 필요합니다. 유엔 자료에 따르면, 65세 이상 인구는 2022년 10%에서 2050년 16%까지 증가할 것으로 예상됩니다. 전 세계 65세 이상 인구는 5세 미만 아동 수의 2배, 12세 아동 수와 맞먹을 것으로 예측됩니다. 이는 노화에 따른 척추 질환의 증가를 의미하며, 효과적이고 최소침습적인 치료법에 대한 수요가 증가하고 있습니다. 예를 들어, 자연 치유 과정을 돕는 생물학은 고령화되는 세계 인구의 증가하는 건강 관리 요구 사항에 부합하며, 이러한 요구를 충족시키는 데 특히 적합합니다.
목차
제1장 서문
제2장 조사 범위와 조사 방법
조사 목적
이해관계자
데이터 소스
1차 정보
2차 정보
시장 추정
상향식 접근
하향식 접근
예측 방법
제3장 주요 요약
제4장 소개
제5장 세계의 척추 바이오로직스 시장
시장 개요
시장 실적
COVID-19의 영향
시장 예측
제6장 시장 내역 : 제품별
척추 동종이식
주요 부문
기계가공 뼈 동종이식
탈회골기질
골이식 대체물
주요 부문
골형성 단백질
합성 골이식
셀 기반 매트릭스
제7장 시장 내역 : 수술 유형별
개흉 척추 수술
최소침습 척추 수술
제8장 시장 내역 : 최종사용자별
병원
외래 진료 센터
척추 수술 센터
정형외과 클리닉
기타
제9장 시장 내역 : 지역별
북미
미국
캐나다
아시아태평양
중국
일본
인도
한국
호주
인도네시아
기타
유럽
독일
프랑스
영국
이탈리아
스페인
러시아
기타
라틴아메리카
브라질
멕시코
기타
중동 및 아프리카
제10장 SWOT 분석
제11장 밸류체인 분석
제12장 Porter's Five Forces 분석
제13장 가격 분석
제14장 경쟁 구도
시장 구조
주요 기업
주요 기업 개요
Arthrex Inc
Alphatec Holdings Inc.
Exactech Inc
Johnson & Johnson
Medtronic plc
NuVasive Inc
Orthofix Medical Inc.
Stryker Corporation
Wright Medical Group N.V.
Zimmer Biomet
KSM
영문 목차
영문목차
The global spine biologics market size reached USD 2.14 Billion in 2024. Looking forward, IMARC Group expects the market to reach USD 2.97 Billion by 2033, exhibiting a growth rate (CAGR) of 3.52% during 2025-2033. The market is driven by the widespread adoption of minimally invasive surgeries (MIS), the growing geriatric population, the growing access to healthcare services on account of inflating income levels, and the increasing incidence of spinal disorders.
Spine Biologics Market Analysis:
Major Market Drivers: The spine biologics market research indicates that the market is primarily driven by the increasing prevalence of spinal disorders such as disc disease and spinal stenosis, often related to aging and lifestyle factors.
Key Market Trends: There is a noticeable trend toward the use of biologics in spine surgeries to promote quicker recovery and better outcomes, aligning with advancements in medical technologies. In the spine biologics market forecast, the industry will witness ongoing innovation with the integration of artificial intelligence and machine learning technologies to enhance the precision and effectiveness of spine biologics.
Geographical Trends: North America currently leads the global market due to its advanced healthcare infrastructure, high healthcare expenditure, and awareness of spinal ailments. Moreover, the Asia-Pacific region is witnessing rapid growth according to the spine biologics market statistics owing to increasing healthcare access, rising economic standards, and a growing geriatric population.
Competitive Landscape: Some of the major market players in the spine biologics industry include Arthrex Inc., Alphatec Holdings Inc., Exactech Inc., Johnson & Johnson, Medtronic plc, NuVasive Inc., Orthofix Medical Inc., Stryker Corporation, Wright Medical Group N.V., and Zimmer Biomet, among many others.
Challenges and Opportunities: The challenges in the market include concerns over the high cost of biologic products and stringent regulatory environments that can delay product launches. As outlined in the spine biologics market overview, the growing collaborations with insurance providers and healthcare facilities hold the potential to improve access to and uptake of biologic treatments generating numerous opportunities.
Spine Biologics Market Trends:
Increasing Prevalence of Spinal Disorders
The growing occurrence of spinal disorders is affecting the spine biologics market growth. In addition, the increasing life expectancy, and lifestyle issues, are spurring the development of degenerative illnesses such as disc disease and spinal stenosis. According to the World Health Organization (WHO) in 2020 approximately 1 in 13 individuals equating to 619 million individuals experienced low back pain (LBP), a 60% increase from 1990. It is further estimated that low back pain cases will increase by around 843 million by 2050 which emphasizes the widespread nature of spinal issues. The rising number of incidences is with the age group of 80 years, and the increasing number of LBP cases occur at the age of 50-55 years. This widespread prevalence necessitates ongoing development and deployment of effective treatments, including biologics, which help promote bone growth and healing, making them critical in treating these pervasive conditions.
Rising Adoption of Minimally Invasive Surgeries (MIS)
Minimally invasive surgeries (MIS) for spinal conditions are preferred due to their less distressful nature and quicker recovery times compared to traditional open surgeries. The global market for minimally invasive surgery is projected to expand at a compound annual growth rate (CAGR) of roughly 6% during 2024-2032 as per the IMARC GROUP. It reached US$ 52.9 Billion in 2023 and anticipates the market to reach US$ 91.0 Billion by 2032. This growth is declarative of a shift in surgical methods that reduce hospital stays and recovery periods, which is particularly beneficial for spine biologics market value.
Growing Geriatric Population
The growing geriatric population is driving the spine biologics market demand. As individuals age, the risk of developing spinal disorders increases, necessitating more frequent and intensive care. As per the data from the UNITED NATIONS population aged 65 and over is expected to rise from 10% in 2022 to 16% in 2050. It is forecasted that individuals aged 65 years or above globally will double the number of children under age 5 and will be equal to the number of 12-year-old children. It means a rising number of age-associated spinal conditions, escalating the demand for treatments that are effective and minimally invasive. For instance, biologics, which aid in the natural healing processes, are particularly suited to meet these needs, aligning with the growing healthcare requirements of an aging global population.
Spine Biologics Market Segmentation:
Breakup by Product:
Spinal Allografts
Machined Bones Allograft
Demineralized Bone Matrix
Bone Graft Substitutes
Bone Morphogenetic Proteins
Synthetic Bone Grafts
Cell Based Matrix
Bone graft substitutes account for the majority of the market share
Bone graft substitutes offer an alternative to customary bone grafts, stipulating structural support and facilitating bone healing processes in spinal surgeries. These substitutes embrace synthetic materials, allografts, and demineralized bone matrix, and are advocated for their aptitude to endorse bone fusion and curb the need for harvesting bone from the patient's own body, minimizing surgical complications and recovery time. As per the statistics by IMARC GROUP, the global bone graft and substitute market reached US$3.2 Billion in 2023. It is estimated to reach US$ 5.1 Billion by 2032 with a compound annual growth rate (CAGR) of 5.2% during 2024-2032. Moreover, various advancements in biomaterials, regenerative medicine, and bone graft substitutes are witnessing increasing adoption in spinal procedures, thus positively increasing the spine biologic market value.
Breakup by Surgery Type:
Open Spine Surgery
Minimally Invasive Spine Surgery
Minimally invasive spine surgery holds the largest share of the industry
Minimally invasive spine surgery is primarily attributed to the growing preference for minimally invasive procedures among patients and healthcare providers. Minimally invasive spine surgery offers several advantages over traditional open surgeries, including smaller incisions, reduced blood loss, shorter hospital stays, and faster recovery times. As a result, it has gained popularity for treating various spinal conditions, such as degenerative disc disease, herniated discs, spinal stenosis, and vertebral fractures. According to the NATIONAL LIBRARY OF MEDICINE, minimally invasive spine (MIS) surgery has advanced significantly with imaging navigation systems, robotics, and endoscopy. More than 400,000 cases are accomplished in the United States annually with spine fusion being the commonly conducted and established treatment options for spine trauma, tumors, structural deformities, and degenerative disorders.
Breakup by End User:
Hospitals
Ambulatory Care Centers
Spinal Surgery Centers
Orthopedic Clinics
Others
Hospitals represent the leading market segment
Hospitals are major centers for specialized medical care that attract a considerable proportion of patients seeking treatments for several forms of spinal disorders including those that necessitate surgeries. Furthermore, some hospitals have dedicated spine centers or departments where they offer services, making them the preferred centers for comprehensive source care. Besides this, hospitals have strong collaborations with spine biologic manufacturers and suppliers, thereby enhancing the efficiency of the equipment. In June 2022, Xenco Medical broadened its range of devices for ambulatory surgery centers by securing Food and Drug Administration (FDA) clearance and introducing its Multilevel CerviKit for their single use. It comprises a complete suite of implants and single-use instruments for two, three, and four level procedures of the anterior cervical spine.
Breakup by Region:
North America
United States
Canada
Asia-Pacific
China
Japan
India
South Korea
Australia
Indonesia
Others
Europe
Germany
France
United Kingdom
Italy
Spain
Russia
Others
Latin America
Brazil
Mexico
Others
Middle East and Africa
North America leads the market, accounting for the largest spine biologics market share
The report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America represents the largest regional market for spine biologics.
North America's dominance in the market can be attributed to highly developed healthcare infrastructure, the high rate of innovative medical technologies' adoption, and a large patient pool with spinal disorders. For instance, as per the data from the National Spinal Cord Injury Association, approximately 450,000 individuals reside in the United States with a spinal cord injury (SCI). Annually, an estimated 17,000 new cases of SCI arise in the U.S., predominantly stemming from trauma to the vertebral column. Thus, the increasing incidence of SCI population is significantly escalating the demand for spine biologics to treat disorders across the region. Additionally, favorable reimbursement policies, strong R&D efforts, and awareness of the advantages of minimally invasive surgical procedures are generating the spine biologics market revenue in North America.
Competitive Landscape:
The spine biologics market research report has also provided a comprehensive analysis of the competitive landscape in the market. Detailed profiles of all major companies have also been provided. Some of the major market players in the spine biologics industry include Arthrex Inc., Alphatec Holdings Inc., Exactech Inc., Johnson & Johnson, Medtronic plc, NuVasive Inc., Orthofix Medical Inc., Stryker Corporation, Wright Medical Group N.V., and Zimmer Biomet.
At present, key players in the market are investing in research and innovation to develop models that outperform rivals and offer solutions sought by customers. They also work hard to ensure their products remain in the market and meet customers' demands through the development of strategic alliances, acquisitions, and expansions into new markets to penetrate more markets and meet all customer needs. For instance, in October 2023, Orthofix Medical Inc., a prominent global spine and orthopedics corporation unveiled the full commercial release of OsteoCove, which is an innovative bioactive synthetic graft, following its 510k clearance. It is offered in putty and strip forms, meticulously developed to offer exceptional bone-forming capabilities and optimal handling properties for various spine and orthopedic procedures. Moreover, excellent marketing and brand management also make their products highly demanded, which is providing a positive spine biologics market outlook.
Key Questions Answered in This Report
1.How big is the global spine biologics market?
2.What is the expected growth rate of the global spine biologics market during 2025-2033?
3.What are the key factors driving the global spine biologics market?
4.What has been the impact of COVID-19 on the global spine biologics market?
5.What is the breakup of the global spine biologics market based on the product?
6.What is the breakup of the global spine biologics market based on the surgery type?
7.What is the breakup of the global spine biologics market based on the end user?
8.What are the key regions in the global spine biologics market?
9.Who are the key players/companies in the global spine biologics market?
